₆W Kruis

Summary for 2004 [at-glance overview of W Kruis work for the selected year as suggested by data mining algorithms]

This is an Authoratory overview of author W Kruis. According to available data, in 2004 W Kruis published at least 6 articles. This work was completed in collaboration with several authors including Schreiber, S and Schölmerich, J. Many other authors have collaborated with W Kruis as well. There is no information about the funding or the grants awarded to support this work.

W Kruis has rank 17 when compared to all other authors using the keyword Colitis, Ulcerative. Analysis of the article abstracts and the titles suggests that W Kruis professional interests are focused around "inflammatory bowel disease", "escherichia coli nissle" and "probiotics inflammatory bowel". These might also be referred to as "inflammatory bowel", "bowel disease" or "ulcerative colitis". Statistical analysis shows that W Kruis's writing is likely to contains terms "disease", "inflammatory", "bowel", "colitis", "ulcerative" and "probiotic".

Unfortunately, there is not enough information to establish W Kruis affiliation. Luckily, several email addresses are on file.

EN FR ES RU

Inaccurate information, needs improvement

make correction leave comment ask question

Images [images we found on the Internet for W Kruis]

Do you know W Kruis who matches the profile above? Click the photo and let us know!

Alternative names (1) [other authors with names similar to W Kruis]

₁₅Kruis, Wolfgang

Year 2004 Charts [W Kruis frequent coauthors and the most common unique vocabulary terms for the selected year]

Historical Performance Charts [graphical overview of W Kruis publication and funding history for the range of years]

Emails (2) [email addresses extracted from W Kruis affiliations]

hidden to prevent spam, click here to reveal

W Kruis Coauthors (36) [all coauthors with the number of joint publications]

2

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

Other [context-specific ads]

Affiliations (5) [condensed summary of the W Kruis affiliations, the leading number and the color conveys importance]

₂Evangelisches Krankenhaus Kalk, Teaching Hospital for the University of Cologne, Germany.
₁Evangelisches Krankenhaus Kalk, Innere Abteilung.
₁Medizinische Klinik I mit Schwerpunkt Gastroenterologie/Infektiologie/Rheumatologie, Charité, Universitätsmedizin Berlin.
₁Abt. Innere Medizin, Evangelisches Krankenhaus Köln-Kalk.
₁Ev. Krankenhaus Kalk, Akad. Lehrkrankenhaus der Universität zu Köln, Buchforststr. 2 D-51103 Köln.

Key Opinion Leader In [W Kruis is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors]

₁₇Colitis, Ulcerative | ₃₆Remission Induction | ₆₅Anti-Inflammatory Agents, Non-Steroidal | ₁₉₄Recurrence

Keywords (32) [keywords assigned to W Kruis articles by PubMed, the leading number and the color conveys importance]

₆Humans | ₅Colitis, Ulcerative | ₄Remission Induction | ₃Recurrence | ₃Anti-Inflammatory Agents, Non-Steroidal | ₃Female | ₃Male | ₂Immunosuppressive Agents | ₂Crohn Disease | ₂Aminosalicylic Acids | ₂Probiotics | ₂Adult | ₂Drug Therapy, Combination | ₁Adolescent | ₁Glucocorticoids | ₁Rare Diseases | ₁Azathioprine | ₁Mesalamine | ₁Colorectal Neoplasms | ₁Child | ₁Administration, Rectal | ₁Placebos | ₁Administration, Oral | ₁Pouchitis | ₁Aspirin | ₁Escherichia coli | ₁Disease Progression | ₁Evidence-Based Medicine | ₁Comorbidity | ₁Proctitis | ₁Suppositories | ₁Inflammatory Bowel Diseases

W Kruis Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; W Kruis might be a good expert witness on these terms]

₁₂disease | ₁₁inflammatory | ₁₁bowel | ₇colitis | ₇ulcerative | ₇probiotic | ₇therapy | ₇patients | ₆coli | ₆probiotics | ₆nissle | ₆mesalazine | ₅antibiotics | ₅treatment | ₄therapeutic | ₄escherichia | ₄maintaining | ₄evidence | ₄efficacy | ₄remission | ₃clinical | ₃microorganisms | ₃standard | ₃specific | ₃effective | ₃enteric | ₃flora | ₂safety | ₂drug | ₂relapses | ₂results | ₂studies
₁₁inflammatory bowel | ₁₀bowel disease | ₇ulcerative colitis | ₆coli nissle | ₄escherichia coli | ₄maintaining remission | ₃enteric flora | ₃standard mesalazine | ₃mesalazine patients | ₃probiotics inflammatory | ₂remission ulcerative | ₂review article | ₂article antibiotics | ₂colitis probiotic | ₂maintenance therapy | ₂nissle effective | ₂probiotic escherichia | ₂antibiotics probiotics | ₂effective standard | ₂probiotic drug | ₂patients ulcerative | ₂therapy ulcerative | ₁digestive metabolic | ₁microorganisms exert | ₁probiotics contain | ₁globally established | ₁compound metronidazole | ₁activity indices | ₁therapy mesalazine | ₁efficacy safety | ₁mixture eight | ₁methods total
₁₀inflammatory bowel disease | ₄escherichia coli nissle | ₃probiotics inflammatory bowel | ₂nissle effective standard | ₂effective standard mesalazine | ₂maintaining remission ulcerative | ₂coli nissle effective | ₂antibiotics probiotics inflammatory | ₂colitis probiotic escherichia | ₂standard mesalazine patients | ₂article antibiotics probiotics | ₂review article antibiotics | ₂remission ulcerative colitis | ₂probiotic escherichia coli | ₂ulcerative colitis probiotic | ₂therapy ulcerative colitis | ₂patients ulcerative colitis | ₂mesalazine patients ulcerative | ₁pathogenic role enteric | ₁effective probiotics clinical | ₁current treatments probiotics | ₁safety profile tolerability | ₁inflammatory bowel diseases | ₁indices rachmilewitz histology | ₁disease unspecific protective | ₁based consensus conference | ₁disease inflammatory bowel | ₁protective measure address | ₁single antibiotic compound | ₁pathogenesis inflammatory bowel | ₁results evidence based | ₁industry study lasted

Reader's Comments (0) [comments posted by readers of W Kruis profile]